Maxim R. Kuznetsov

Maxim R. Kuznetsov

Auto-generated profile, based on publicly available information

Maxim R. Kuznetsov

Sechenov First Moscow State Medical University (Sechenov University)

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 December 2018 in Kardiologiia
Verified
Journal Article
Closed access
PDF file
MKM. R. Kuznetsov
M. R. Kuznetsov
IRI. V. Reshetov
I. V. Reshetov
BOB. B. Orlov
B. B. Orlov
AKA. A. Khotinsky
A. A. Khotinsky
AAA. A. Atayan
A. A. Atayan
MSM. A. Shchedrinа
M. A. Shchedrinа
Purpose: to elucidate predictors of development of chronic thromboembolic pulmonary hypertension (CTEPH) after acute pulmonary artery thromboembolism (PTE). Material and methods . We included in this study 210 patients hospitalized with diagnosis of submassive and massive PTE from 2013 to 2017. In 1 to 3 years after initial hospitalization these patients were invited for control examination. According to results of this examination patients were divided into two groups: with (group 1, n=45) and without (group 2, n=165) signs of CTEPH. Severity of pulmonary artery vascular bed involvement was assessed by multislice computed tomography (MSCT) angiography and lung scintigraphy. For detection of thrombosis in the inferior vena cava system we used ultrasound angioscanning. Examination also included echocardiography. Results. In the process of mathematical analysis, the following risk factors for the development of CTEPH embolism were determined: duration of thrombotic history (group 1 – 13.70±2.05 days, group 2– 16.16±1.13 days, p=0.015), localization of venous thrombosis in the lower extremities (the most favorable – shin veins, popliteal, and common femoral veins, unfavorable – superficial femoral vein). The choice of the drug for thrombolytic and anticoagulant therapy: streptokinase and urokinase were significantly more effective than alteplase, rivaroxaban was superior to the combination of unfractionated or low molecular weight heparins with warfarin. Also, risk factors for the development of CTEPH were the initial degree of pulmonary hypertension and tricuspid insufficiency, as well as the positive dynamics of these indicators at the background of thrombolytic or anticoagulant therapy. Of concomitant diseases, significant risk factors for development of CTEPH were grade 3 hypertensive disease, diabetes mellitus, post­infarction cardiosclerosis. On the other hand, age, gender, degree of severity at the time of admission, presence of infarction pneumonia, surgical prevention of recurrent pulmonary embolism, number of pregnancies and deliveries, history of trauma and malignancies, cardiac arrhythmias produced no significant impact on the development of CTEPH.

1 January 2021 in Russian Medical Inquiry
Verified
Journal Article
Open access
MKM.R. Kuznetsov
M.R. Kuznetsov
IRI.V. Reshetov
I.V. Reshetov
SSS.V. Sapelkin
S.V. Sapelkin
NYN.V. Yasnopol’skaya
N.V. Yasnopol’skaya
MHMoscow S.S. Yudin City Clinical Hospital
Moscow S.S. Yudin City Clinical Hospital
This paper discusses the issues emerging during the treatment of lower-limb arterial diseases and intermittent claudication. According to the international and Russian guidelines, the common management strategy for intermittent claudication is as follows: conservative treatment is recommended in patients without limiting intermittent claudication who can walk 30 m or more without pain. Drugs that are prescribed is these patients are addressed. No large well-designed studies on most of these drugs were conducted, therefore, it is challenging to assess their efficacy in patients with intermittent claudication. The authors focus on cilostazol that has the largest evidence base. This drug is included in the Russian and international clinical guidelines. Several students demonstrate that cilostazol provides antithrombotic effect, stabilizes atherosclerotic plaques, prevents hyperplasia of neointima and restenosis after vascular procedures, improves lipid metabolism, and significantly increases pain-free walking distance (intermittent claudication distance). Recent studies show that cilostazol can be used in the complex treatment for COVID-19 due to pleiotropic mechanism of action. KEYWORDS: lower-limb arterial diseases, intermittent claudication, conservative treatment, cilostazol, COVID-19, restenosis, antiplatelet therapy. FOR CITATION: Kuznetsov M.R., Reshetov I.V., Sapelkin S.V., Yasnopol’skaya N.V. Conservative treatment for intermittent claudication. Russian Medical Inquiry. 2021;5(4):212–217 (in Russ.). DOI: 10.32364/2587-6821-2021-5-4-212-217.

27 January 2025 in Kazan medical journal
Verified
Journal Article
Closed access
PDF file
AVAleksey Vaganov
Aleksey Vaganov
MKMaxim R. Kuznetsov
Maxim R. Kuznetsov
AAAzat B. Artykov
Azat B. Artykov
AAAlexandra V. Anisimova
Alexandra V. Anisimova
ANAshrafulla O. Nasritdinkhodjaev
Ashrafulla O. Nasritdinkhodjaev
КРКузнецов Максим Робертович
Кузнецов Максим Робертович
BACKGROUND: The development of new and more precise methods for determining the boundary between necrotic and viable tissue is essential for accurately determining the level of amputation. AIM: The study aimed to evaluate the first results of ultraviolet photoluminescence spectroscopy in determining the level of the proposed amputation of the lower limb. METHODS: This prospective, open-label, and non-randomized study included 20 patients with critical lower limb ischemia and suspected toe gangrene who underwent percutaneous transluminal balloon angioplasty. The patients were divided into two groups. Group 1 (n = 10) included patients who did not require major limb amputation during follow-up, whereas group 2 (n = 10) included patients who underwent above-knee amputation during follow-up. The groups were comparable in age (62.5 [53.25; 74.5] years in group 1; 65.5 [60.5; 76] years in group 2; p = 0.352). All patients underwent clinical monitoring and serial photoluminescence measurements of the affected limb using a device composed of a laser radiation source (diode laser) as the excitation signal and a mini-spectrometer for signal detection. Measurements were performed during hospitalization and at re-admission. The luminescence amplitude was correlated with the clinical manifestations of critical limb ischemia during inpatient treatment and at follow-up hospitalization. A one-month post-discharge telephone follow-up was conducted to monitor patient status. In cases of recurrent critical ischemia and gangrene progression, patients were re-hospitalized for above-knee re-amputation. The results are presented as mean values, standard deviations, or medians with the 25th and 75th percentiles. RESULTS: Following vascular reconstruction of the affected limb, a statistically significant decrease in luminescence amplitude was observed at 400 and 420 nm (nicotinamide adenine dinucleotide peak) and 450 nm (negative hemoglobin peak) in group 1 compared with preoperative levels in the critical ischemia zone (98.5 [52.9; 508.6] × 10⁵ photons before surgery; 81.5 [42.9; 117.4] × 10⁵ photons after surgery; p = 0.001]). No significant amplitude changes were observed in group 2 before and after surgery (p = 0.245). In the gangrene zone, all amplitude values at 400–600 nm exhibited minimal intensity values. Near the visible boundary between necrotic and healthy tissue, a sharp increase in photoluminescence amplitude was detected, with a difference of 81.2 (42.9; 120.4) × 10⁵ photons at 450 nm. CONCLUSION: Laser-induced ultraviolet photoluminescence spectroscopy may serve as a potential method for determining the precise level of amputation in cases of dry gangrene of the lower limb.

22 May 2023 in Ambulatornaya khirurgiya = Ambulatory Surgery (Russia)
Verified
Journal Article
Open access
PDF file
ACA. I. Chernookov
A. I. Chernookov
MKM. R. Kuznetsov
M. R. Kuznetsov
NKN. Yu. Korobova
N. Yu. Korobova
SKS. I. Kandyba
S. I. Kandyba
AAA. A. Atayan
A. A. Atayan
APA. Z. Pshmakhova
A. Z. Pshmakhova
Introduction. The wide prevalence of varicose veins of the lower extremities and relapses of this disease causes a frequent combination of this pathology with other surgical and traumatological diseases. The expediency of using simultaneous operations is manifested in their obvious economic advantages.Objective. To substantiate the expediency and effectiveness of simultaneous laser thermal obliteration of recurrent veins of the lower extremities and Baker’s cyst.Materials and methods. 9 patients with recurrent varicose veins and Baker’s cyst were operated on. Of these, there were 7 (77.8%) women and 2 (22.2%) men, the average age was 52.8 ± 0.2 years. The average duration of the incidence of varicose veins was 14.1 ± 0.3 years, Baker’s cyst – 3.5 ± 0.1 years. As planned, patients underwent simultaneous laser endovenous coagulation of recurrent veins and intracavitary thermal obliteration of Baker’s cyst.Results. There were no complications, the duration of operations was 40.3 ± 0.4 minutes. The intensity of the pain syndrome in 6–8 hours after surgery was 4.1 ± 0.2 points. On the 10th day, no pain was observed in any patient. The duration of pain was 7.8 ± 0.4 days. Long-term results were studied 12–16 months after completion of treatment in 9 (100%) patients. Recurrent varicose veins were not detected. In 8 (88.9%) patients, complete obliteration of Baker’s cyst was established.Conclusions. Reliable obliteration of Baker’s cyst and recurrent varicose veins, 100% technical success, disappearance of clinical symptoms of this pathology, absence of relapses of both diseases in 8 (88.9%) patients after 12-16 months indicates high efficiency and indisputable prospects of such an approach to the treatment of this category of patients. However, the study is based on a small number of observations, so further accumulation of experience is required to generalize the results of the study.

15 September 2016
Verified
Journal Article
Closed access
MKM R Kuznetsov
M R Kuznetsov
SSS V Sapelkin
S V Sapelkin
BBB V Boldin
B V Boldin
SLS G Leont'Ev
S G Leont'Ev
LNL A Neskhodimov
L A Neskhodimov

1 January 2020 in Doctor.Ru
Verified
Journal Article
Open access
MKM.R. Kuznetsov
M.R. Kuznetsov
RMRussian Federation Moscow
Russian Federation Moscow
OPO.V. Papysheva
O.V. Papysheva
BOB.B. Orlov
B.B. Orlov
ISI.V. Sorokina
I.V. Sorokina
Гормоны и сосуды: pro et contra